EBS Reports That Its NEXT WAVE™ Brain Stimulation Device Expanded the Visual Field by a Mean Average of 24% in a …

BERLIN--(BUSINESS WIRE)--

EBS Technologies GmbH, an emerging medical device company developing the revolutionary NEXT WAVE brain stimulation platform for treatment of vision deficits caused by neurological disorders, announced today the results of a multi-center, 82-patient clinical trial of its NEXT WAVE brain stimulation device.

About one-half of the clinical trial patients were given a 40-minute treatment protocol for 10 consecutive days with the NEXT WAVE device. With a mean increase of 24%, NEXT WAVE-treated patients showed significantly better improvements in stimulation of their total visual field compared to patients in the control group, which did not receive NEXT WAVE stimulation. All patients had vision impairment lasting at least six months prior to the clinical trial and had exhausted all standard therapeutic options to improve their vision.

There is a huge unmet clinical need for the treatment of vision impairment caused by a variety of different neurological disorders, such as neuropathy of the optic nerve, brain injury or stroke. For example, stroke alone is the worlds third-leading cause of death as well as the leading cause of serious, long-term disability. There are more than 10.4 million stroke survivors with long-term disability in Europe and the U.S. Three out of five of these disabled persons are potentially treatable with our NEXT WAVE therapy once we commence commercialization, said Ulf Pommerening, CEO of EBS Technologies.

We look forward to expanding the scientific evidence for the efficacy of our NEXT WAVE approach, especially in stroke patients, in an expanded clinical trial that will commence imminently, said Pommerening.

About NEXT WAVE

The NEXT WAVE technology enables a unique revitalization of selective communication paths between neurological cells, which may have been lost due to brain injury caused by trauma, stroke or tumor resection. The non-invasive therapy utilizing the patented NEXT WAVE technology is clinically validated to restore vision impairment by 20 to 30 percent after brain dysfunction. In addition, glaucoma patients have shown to benefit from the NEXT WAVE technology.

NOTE: NEXT WAVE is approved for sale in Europe; it is not approved for sale or investigational use in the U.S.

Read the original post:
EBS Reports That Its NEXT WAVE™ Brain Stimulation Device Expanded the Visual Field by a Mean Average of 24% in a ...